CoChat

CSF Cytokines in Aging, Multiple Sclerosis, and Dementia

Open access
Hu, William T., Howell, Jennifer Christina, Ozturk, Tugba, Gangishetti, Umesh, Kollhoff, Alexander L., Hatcher-Martin, Jaime M., Anderson, Albert M., Tyor, William R. · 2019 · Frontiers in Immunology
Cited by 122

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Inflammation is a common process involved in aging, multiple sclerosis (MS), and age-related neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), but there is limited evidence for the effects of aging on inflammation in the central nervous system. We collected cerebrospinal fluid (CSF) from 105 healthy control subjects representing a wide age range (23-86), and analyzed levels of cytokines associated innate immunity (TNF-α) and different T-helper subtypes: interferon-gamma induced protein 10 (IP-10) for Th1, interleukin-10 (IL-10) for Th2, and interleukin 8 (IL-8/CXCL8) for Th17. We show that CSF levels of TNF-α, IP-10, and IL-8 all increased linearly with age, but levels of IL-10 demonstrated a U-shaped relationship with age. We further found greater age-related increases in TNF-α, IL-10, and IL-8 relative to increases in IP-10 levels, consistent with a shift from Th1 to other inflammatory phenotypes. Finally, when we analyzed the same four cytokines in people with neurological disorders, we found that MS and AD, but not PD or dementia with Lewy bodies, further accentuated the age-related shift from Th1- to non-Th1-related cytokines. We propose that CSF cytokine levels represent powerful surrogates of brain inflammation and aging, and some, but not all, neurological disorders accelerate the shift away from Th1 phenotypes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2019.00480

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 38

  1. Lapenna, 2018, Perivascular macrophages in health and disease, Nat Rev Immunol., 18, 689, 10.1038/s41577-018-0056-9 · DOI · Paper page
  2. Skaper, 2018, An Inflammation-centric view of neurological disease: beyond the neuron, Front Cell Neurosci., 12, 72, 10.3389/fncel.2018.00072 · DOI · Paper page
  3. Hu, 2010, Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment, Acta Neuropathol., 119, 669, 10.1007/s00401-010-0667-0 · DOI · Paper page
  4. Sandmand, 2002, Is ageing associated with a shift in the balance between Type 1 and Type 2 cytokines in humans?, Clin Exp Immunol., 127, 107, 10.1046/j.1365-2249.2002.01736.x · DOI · Paper page
  5. Hu, 2015, CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?, Ann Clin Transl Neurol., 2, 131, 10.1002/acn3.160 · DOI
  6. Howell, 2016, Research lumbar punctures among African Americans and Caucasians: perception predicts experience, Front Aging Neurosci., 8, 296, 10.3389/fnagi.2016.00296 · DOI · Paper page
  7. Howell, 2017, Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers, Alzheimers Res Ther., 9, 88, 10.1186/s13195-017-0315-1 · DOI · Paper page
  8. Gangishetti, 2018, Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease, Alzheimers Res Ther., 10, 98, 10.1186/s13195-018-0426-3 · DOI
  9. Clark, 2007, How TNF was recognized as a key mechanism of disease, Cytokine Growth Factor Rev., 18, 335, 10.1016/j.cytogfr.2007.04.002 · DOI · Paper page
  10. Hunt, 2003, Cytokines: accelerators and brakes in the pathogenesis of cerebral malaria, Trends Immunol., 24, 491, 10.1016/S1471-4906(03)00229-1 · DOI · Paper page
  11. Pelletier, 2010, Evidence for a cross-talk between human neutrophils and Th17 cells, Blood., 115, 335, 10.1182/blood-2009-04-216085 · DOI · Paper page
  12. Haabeth, 2011, Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer, Nat Commun., 2, 240, 10.1038/ncomms1239 · DOI · Paper page
  13. Craig-Schapiro, 2011, Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis, PLoS ONE., 10.1371/journal.pone.0018850 · DOI · Paper page
  14. Uzawa, 2009, Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis, J Neurol., 256, 2082, 10.1007/s00415-009-5274-4 · DOI
  15. Horellou, 2015, Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis, J Neuroimmunol., 289, 1, 10.1016/j.jneuroim.2015.10.002 · DOI
  16. Matejcikova, 2015, Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: a pilot study, J Neural Transm., 122, 273, 10.1007/s00702-014-1244-9 · DOI
  17. Sosvorova, 2015, The comparison of selected cerebrospinal fluid and serum cytokine levels in patients with multiple sclerosis and normal pressure hydrocephalus, Neuro Endocrinol Lett., 36, 564, 10.1046/j.1365-2249.2002.01736.x · DOI · Paper page
  18. Nevalainen, 2015, Transcriptomic and epigenetic analyses reveal a gender difference in aging-associated inflammation: the vitality 90+ study, Age., 37, 9814, 10.1007/s11357-015-9814-9 · DOI
  19. Pangrazzi, 2017, Inflamm-aging influences immune cell survival factors in human bone marrow, Eur J Immunol., 47, 481, 10.1002/eji.201646570 · DOI · Paper page
  20. Rhinn, 2017, Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes, Cell Syst., 4, 404, 10.1016/j.cels.2017.02.009 · DOI · Paper page
  21. Cheng, 2018, Repression of human and mouse brain inflammaging transcriptome by broad gene-body histone hyperacetylation, Proc Natl Acad Sci USA., 115, 7611, 10.1073/pnas.1800656115 · DOI
  22. Fainardi, 2003, Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings, J Neuroimmunol., 142, 149, 10.1016/S0165-5728(03)00266-2 · DOI
  23. Braitch, 2008, Increased osteopontin levels in the cerebrospinal fluid of patients with multiple sclerosis, Arch Neurol., 65, 633, 10.1001/archneur.65.5.633 · DOI · Paper page
  24. Maxeiner, 2014, Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases, Cytokine., 69, 62, 10.1016/j.cyto.2014.05.008 · DOI
  25. Cossburn, 2012, Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis, Mult Scler., 18, 45, 10.1177/1352458511417479 · DOI · Paper page
  26. Roy, 2017, Differential effects of aging on motor and cognitive functioning in multiple sclerosis, Mult Scler., 23, 1385, 10.1177/1352458516679036 · DOI
  27. Sawcer, 2011, The major cause of multiple sclerosis is environmental: genetics has a minor role–no, Mult Scler., 17, 1174, 10.1177/1352458511421106 · DOI
  28. Maimone, 1991, Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis, J Neuroimmunol., 32, 67, 10.1016/0165-5728(91)90073-G · DOI · Paper page
  29. Sorensen, 1999, Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients, J Clin Invest., 103, 807, 10.1172/JCI5150 · DOI · Paper page
  30. Narikawa, 2004, CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis, J Neuroimmunol., 149, 182, 10.1016/j.jneuroim.2003.12.010 · DOI
  31. Rossi, 2014, Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration, Mult Scler., 20, 304, 10.1177/1352458513498128 · DOI
  32. de, 2018, Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls, PLoS ONE., 13, e0192516, 10.1371/journal.pone.0192516 · DOI
  33. Rodriguez-Sainz, 2002, Th1/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis, Eur Cytokine Netw., 13, 110
  34. Khademi, 2000, Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis, J Neuroimmunol., 103, 202, 10.1016/S0165-5728(99)00184-8 · DOI
  35. Mellergard, 2010, Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid, Mult Scler., 16, 208, 10.1177/1352458509355068 · DOI · Paper page
  36. Mrak, 1997, Aging-associated changes in human brain, J Neuropathol Exp Neurol., 56, 1269, 10.1097/00005072-199712000-00001 · DOI · Paper page
  37. Ma, 2017, Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice, Nat Commun., 8, 1434, 10.1038/s41467-017-01484-6 · DOI · Paper page
  38. Thewissen, 2005, Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patients, Ann N Y Acad Sci., 1051, 255, 10.1196/annals.1361.066 · DOI · Paper page

Cited by

See all 122

Metadata

Authors
Hu, W. T., Howell, J. C., Ozturk, T., Gangishetti, U., Kollhoff, A. L., Hatcher-Martin, J. M., Anderson, A. M., & Tyor, W. R.
Venue
Frontiers in Immunology
Published
2019-03-15
Volume
10
Pages
480-480
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2922712727
Cited by
122
References
21
FWCI
5.64
Type
journal article
Language
en
Open access
gold
Funders
National Institutes of Health (I01BX01506, K23AG042856, K23MH095679, R01AG054046, R01MH116695, R21AG043885)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CSF Cytokines in Aging, Multiple Sclerosis, and Dementia. https://app.cochat.ai/papers/10.3389/fimmu.2019.00480
The paper
Hu, W. T., Howell, J. C., Ozturk, T., Gangishetti, U., Kollhoff, A. L., Hatcher-Martin, J. M., Anderson, A. M., & Tyor, W. R. (2019). CSF Cytokines in Aging, Multiple Sclerosis, and Dementia. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2019.00480

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.